Next Article in Journal
Approach to Biomarker Testing: Perspectives from Various Specialties
Previous Article in Journal
Real-World Adjuvant TAC or FEC-D for HER2-Negative Node-Positive Breast Cancer in Women Less Than 50 Years of Age
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Open AccessArticle

Retrospective Analysis of the Effect of CAPOX and mFOLFOX6 Dose Intensity on Survival in Colorectal Patients in the Adjuvant Setting

1
Department of Oncology, McGill University, Montreal, QC, Canada
2
Tom Baker Cancer Centre, Calgary, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(3), 171-177; https://doi.org/10.3747/co.23.3059
Received: 3 March 2016 / Revised: 13 April 2016 / Accepted: 9 May 2016 / Published: 1 June 2016
Background: Despite lack of a true comparative study, the folfox (5-fluorouracil–leucovorin–oxaliplatin) and capox (capecitabine–oxaliplatin) regimens are believed to be similar in their efficacy and tolerability in the treatment of stage III colorectal cancer. However, that belief has been disputed, because real-life data suggest that the capox regimen is more toxic, leading to more frequent reductions in the delivered dose intensity—thus raising questions about the effect of dose intensity on clinical outcomes. Methods: A retrospective data review for two Canadian institutions, the Segal Cancer Centre and the Tom Baker Cancer Centre, considered patients diagnosed with stage iii colorectal cancer during 2006–2013. Primary endpoints were dose intensity and toxicity, with a secondary endpoint of disease-free survival. Results: The study enrolled 180 eligible patients (80 at the Segal Cancer Centre, 100 at the Tom Baker Cancer Centre). Of those 180 patients, 75 received capox, and 105 received mfolfox6. In the capox group, a significant dose reduction was identified for capecitabine compared with 5-fluorouracil in mfolfox6 group (p = 0.0014). Similarly, a significant dose reduction was observed for oxaliplatin in mfolfox6 compared with oxaliplatin in capox (p = 0.0001). Compared with the patients receiving capox, those receiving mfolfox6 were twice as likely to experience a treatment delay of more than 1 cycle-length (p = 0.03855). Toxicity was more frequent in patients receiving mfolfox6 (nausea: 30% vs. 18%; diarrhea: 47% vs. 24%; peripheral sensory neuropathy: 32% vs. 3%). At a median follow-up of 40 months, preliminary data showed no difference in disease-free survival (p = 0.598). Pooled data from both institutions were also separately analyzed, and no significant differences were found. Conclusions: Our results support the use of capox despite a lack of head-to-head randomized trial data.
Keywords: capox; mfolfox6; dose intensity; disease-free survival; colorectal cancer capox; mfolfox6; dose intensity; disease-free survival; colorectal cancer
MDPI and ACS Style

Mamo, A.; Easaw, J.; Ibnshamsah, F.; Baig, A.; Rho, Y.S.; Kavan, T.; Batist, G.; Kavan, P. Retrospective Analysis of the Effect of CAPOX and mFOLFOX6 Dose Intensity on Survival in Colorectal Patients in the Adjuvant Setting. Curr. Oncol. 2016, 23, 171-177. https://doi.org/10.3747/co.23.3059

AMA Style

Mamo A, Easaw J, Ibnshamsah F, Baig A, Rho YS, Kavan T, Batist G, Kavan P. Retrospective Analysis of the Effect of CAPOX and mFOLFOX6 Dose Intensity on Survival in Colorectal Patients in the Adjuvant Setting. Current Oncology. 2016; 23(3):171-177. https://doi.org/10.3747/co.23.3059

Chicago/Turabian Style

Mamo, A.; Easaw, J.; Ibnshamsah, F.; Baig, A.; Rho, Y.S.; Kavan, T.; Batist, G.; Kavan, P. 2016. "Retrospective Analysis of the Effect of CAPOX and mFOLFOX6 Dose Intensity on Survival in Colorectal Patients in the Adjuvant Setting" Curr. Oncol. 23, no. 3: 171-177. https://doi.org/10.3747/co.23.3059

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop